Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Miggy. Glad to see you are back among us. Did you grab any cheapies on that dip?
Nothing has changed except CELZ had a great year over year revenue increase and massive debt reduction. Two small notes were added as they wind down commercialization.
This is what the INVESTORS KNOW about CELZ.......but don't trust me or anyone on the blog. Do you own DD please!!
The FDA does not regulate medical procedures performed by qualified and licensed doctors. CaverStem® has the only clinically proven procedure to treat Erectile Dysfunction with adult stem cells in the US. CaverStem® ONLY uses your own adult stem cells (not Embryonic stem cells) and they are not altered, manipulated or stored. Therefore, FDA does not object to these procedures.
CaverStem® has been shown to be effective even in patients who do not respond to PDE5 inhibitors, and, unlike PED5 inhibitors, CaverStem® and FemCelz is safe.
Several doctors in the US have been vetted and signed and are now OPEN and treating patients (Doctors Gershman, Said, Bieri, Liu, Narayan, Niemczyk and Sanderson). Currently you can make an appointment any of those locations along with Dr. Antonini in Rome, Italy.
Two shareholders are among the treated patients and can confirm the ease of the treatment for the patient. Testimonials will be published soon for many happy customers.
CELZ added physicians in Hawaii (Sanderson), California, Ohio, Texas and Tennessee (to be named soon) and CELZ will continually add the new physicians to the CaverStem® website as they come aboard. CELZ has been adding approximately 5 doctors per month in the most recent two months.
To speed up new physician training due to the demand, CELZ added additional medical personnel to travel to each physicians office to train.
Due to the increased international demand and to compliment the existing relationship with Scott Shea, Thomas Bianchi has joined the company as the international sales representative. DD will tell you that interest in increasing in Europe.
Marketing Director David Brandt has been interviewing patients and is preparing customer testimonial videos. These will be posted soon.
CELZ has started treating the first patients with the FemCelz procedure for the treatment of female sexual dysfunction using stem cells from the patient's own bone marrow. Many of the existing CaverStem® affiliated physician's will also treat female patients for sexual function and we anticipate that they will be the leaders in progressing the FemCelz program. Doctors have been treating the first patients with FemCelz and additional doctors are scheduled to be trained in FemCelz procedures.
Over 50 domain names have been registered showing that more doctors are being vetted or have shown interest. These includes MANY cities and states in the USA, and now we KNOW there are domains registered in Russia (PromoMed, Dr. Pushkar), Germany, France, Switzerland (Alto Uro, Dr. Bachmann) and Austria.
CELZ has begun a series of mailer and email campaigns introducing the CaverStem® procedure to licensed physicians in the areas of urology, OB/GYN, sexual function and plastic surgery. This campaign which will be expanded on a monthly basis with follow up mailers and emails and calls from our sales representatives. It's the goal to reach out to a minimum of 2500 new physicians each month by these methods. CELZ reported good replies from the January emails. Your DD will show you that more interest is building each month.
CELZ has also increased its online presence on Social Media and by placing banner advertising on websites and search engines attracting the active male. They are currently scripting television commercials which will be edited to direct patients to each physician in their area.
U.S. and international agreements have been reached for exclusive distribution rights for the FDA approved Generation 2 bone marrow harvest technology which has been used with multiple ED patients with excellent results, however Government exemptions are required for the ongoing import of the device in Russia. This is a slow and tedious process in getting approval, therefore CELZ progress has been delayed in Russia.
Your DD will show that Dr. Gershman has been performing the procedure with EXCELLENT results…Up to 90% success rate, even in difficult patients. CELZ has received positive feedback from treating physicians of a 70% to 90% efficacy in their patients. Obviously results differ depending on the age and health of the patient and cause and severity of their erectile dysfunction.
A one-year trial has concluded and will PROVE the same results. You can watch for results here; https://clinicaltrials.gov/ct2/show/NCT03699943?recrs=deghi&fund=2&lupd_s=09%2F27%2F2018&lupd_d=14
CELZ is working on their paper for publication. The Principal Investigator is Dr. Jacob Rajfer, MD University of California, Los Angeles... top notch credentials. This is ongoing and in compliance with contractual obligations. Once the paper has been approved by The Journal of Translational Medicine and a publication date advised, shareholders will be updated. Additionally, CELZ has designed an electronic patient registry that is intended to include data from the clinical trial, data from treating physicians using centrifuge technology with a 30cc to 60cc bone marrow aspiration and the second generation, needle only.
Revenue has now started, CELZ is cash flowing. Additional physicians are scheduled for training, patients are being treated and revenues are being generated and increasing each month. Evidence of this are the scores of patients treated in Rome and NM. CELZ anticipates reaching financial self-sufficiency by revenues from sales in 2019.
CELZ has Institutional Investors now, slowing dilution and providing much better terms as CELZ completes the commercialization phase. Two of the most recent notes that were issued in 2018 were renegotiated providing cash for operations.
CELZ signed with PatientGain to redesigning the website for the anticipated HUGE volume of traffic CaverStem® and FemCelz will generate. This has generated many calls to the vetted doctors.
CELZ anticipates acquiring the Virility Centers of America brand from affiliate company Creative Medical Health, Inc. The use of the Virility Centers brand is related to male and female wellness clinics, including sexual function (CaverStem® and FemCelzTM), incontinence and infertility. This brand will compliment the CaverStem® and FemCelz brands.
CaverStem® and FemCelz are just TWO of SEVERAL patents held by CMTH.
4 NEW patents were applied for in 2018.
CELZ anticipates commercialization of StemSpine in late 2019 or early 2020 bringing online a third revenue source.
Management has already successfully commercialized Medistem providing a large return on investment for the shareholders.
CaverStem®, FemCelz, StemSpine & AmnioStem have all be TRADEMARKED
CaverStem is now a REGISTERED TRADEMARK. Caverstem®
We KNOW Caverstem® + FemCelzTM+ StemSpineTM + AmnioStemTM = NASDAQ
PLEASE read the sticky posts seen when logging in to iHub through a browser!!
Totally agree Chaka!
Fully agree MM, but I don’t think it will take that long, unless you hold through AmnioStem like me.
Smart move IMO.
Happy Birthday. Let’s have a day like SFT birthday last year LOL
These rumblings are the same thing I am talking about. Some of the silence from the company is understandable. No one on the OTC likes it, but they are running silent and running deep IMO.
If you step back and look at the connections Gershman has in LA, looks at the excitement from the docs in SF, NM, FL and Rome, you can almost feel the rumble between the doctors about how big CaverStem and FemCelz can be. The company knows this and is not worried about the current PPS. Hard on us. Effing right it is.
It does not take too many more doctors to get set up to have the infrastructure to start fully advertising these treatments and generating patient awareness.
When this happens across the US and Europe and we can see the TV commercials, the entire mood will change here and there will be a chase for shares.
LONG and Strong!!!!!!!
Agreed. We discussed The AS and OS a few times. Way too many things happening to sell, and way too much happening for the company to stay quiet to much longer.
Weaker hands to stronger ;)
Welcome. Smart move if you can wait a bit longer.
The $0.0065 answer is the longs who see what happening will wait it out and keep adding. It’s not hope and trust. It’s what we can see. There were no new notes. There was tons of debt reduction. The revs from the 2019 doctors have not been seen due to account practices. I thought the late Q1 numbers would make it, but they clearly did not.
Nothing that I have posted has changed. You can see they are signing doctors, starting FemCelz, selling kits etc etc.
Since those revs from Rome and NM and all the new doctors did not hit the books in time, doesn’t make it a scam or mean they are all conspiring to lie as some suggest.
I honestly plan to hold as many as possible all the way through AmnioStem commercialization. So even though the PPS is ugly at the moment, it will still be just as beautiful in the future.
There were more BUYS than SELLS yesterday but it was walked down on any sell, maintained on any buy. Go figure. I have a buddy buying a small amount today. He will at least get cheapies. :)
It should. Week hands out. There was more buying today than selling. MM shook out those who they could.
Nothing but good news in the Q. Silly.
And CELZ has that horsepower. That why I like it so much as a long term investment. They are just starting out with CaverStem and FemCelz. And they have StemSpine on deck and the biggie, AmnioStem. AmnioStem has soooo much potential. Many patents, means many revenue sources. We are watching only the beginning.
Out for the day! Go $CELZ
Agreed rrao. They fixed a bunch in that Q. Now we need the PR’s that simply need to follow. Announce the OH, TN, TX doctors, lay out some training schedules, just to start. Time to really start pushing this out to the world. We know it’s all there ready to go.
That is true. I almost forgot about that bro.
Agreed, and he contacted CELZ looking for a fix! https://www.facebook.com/100005110183058/posts/1179510398895955?s=100001535920719&sfns=mo
Could be Meatslice. It will be another three months for the proof many need that will prove these doctors are buying kits by the scores. Those who believe it will be adding all along the way. We will see more and more doctors signing up as well. Something between the Q’s could send this any time IMO. If we have to wait for the next Q, so be it, but the company is clearly improving daily IMO. We should see Sanderson up and running any time IMO, followed by OH, TN, TX and who knows how many more. I think the vids by the doctors will reach other doctors and this could move rapidly between the filings.
$CELZ is setting the stage for something truly remarkable:
Q1 Revenues up 429%
YOY and yet General Expenses were only up 39%
That's amazing efficiency.
Gross PROFIT was up 408%!!! "Due to the increased SALES associated with...the @CaverStem® procedure."
All awesome takeaways from the filing. Imagine where it will be next Q! Loading all I can.
Well said Vulken, spot on!!!
Yes he is SFT. And he has backing from the ministry of health. Just like this is spreading around the US, it will spread around Europe and then spread global. It’s is a great new “fix” that way too many men suffer from.
Just like Narayan said, they have been looking for a non surgical fix for a long time. Everyone is fearful of drugs, so this is the perfect fix at the perfect time. Seeing the doctors excited tells the story.
Business wise, this Q truly showed a ton of great info proving they are coming together as a company. Like NSX opened several weeks ago, there was not as much revs in Q1 because the newest doctors clearly were not generating revs before March 31.
The great thing, like many have posted here, is that it is as clear as day that Rome and NM are rocking it, at the others are are excited AND also treating with FemCelz!!!! Huge info, doubles the potential revenue.
Q2 and Q3 will prove this out, and I agree that CELZ has a great chance of hitting their mark by being self sufficient in 2019.
And don’t forget StemSpine is lurking right behind !!!!!
$CELZ.
The big picture is a beautiful one. We are exactly where we expected overall, except I thought we may have seen more revs from Italy and domestic, but now we know those are simply going to be in Q2. The revenues coming in weekly are not affected at all, just when we can see them. The market is smart and will digest this Q and will see all the good!!!
For sure gint. Those are so important to set things up. You know I will be gone most of the next few days. Keep a lid on our empty boxes boys. $CELZ.
Absolutely. We know Rome and NM are rocking. Just a bit late for this Q. Huge gain year over year. Lots happening. We all know it!!
AMAZING Q!!! The debt reductions and warrant reductions are HUGE. Absolutely fantastic improvements. The warrant exercises are worth $500k in revs, easily IMO. You simply have to understand the implications of this debt picture now. Excellent improvement!!!
Yes you will. Filter back on!!!
Old news we already discussed. LOL
They would have issued 8k on them IMO
Spot on, IMO, but could be higher. The $50,000+ we had Q 3-4 in 2018 were most likely just LA. We added a few offices in February. Do we see a 50% increase in revs, double or more? Regardless, we are moving in the right directions, cash flowing and adding doctors !!!
This is what the INVESTORS KNOW about CELZ.......but don't trust me or anyone on the blog. Do you own DD please, and you too will KNOW......
The FDA does not regulate medical procedures performed by qualified and licensed doctors. CaverStem® has the only clinically proven procedure to treat Erectile Dysfunction with adult stem cells in the US. CaverStem® ONLY uses your own adult stem cells (not Embryonic stem cells) and they are not altered, manipulated or stored. Therefore, FDA does not object to these procedures.
CaverStem® has been shown to be effective even in patients who do not respond to PDE5 inhibitors, and, unlike PED5 inhibitors, CaverStem® and FemCelz is safe.
Several doctors in the US have been vetted and signed and are now OPEN and treating patients (Doctors Gershman, Said, Bieri, Liu, Narayan, Niemczyk and Sanderson). Currently you can make an appointment any of those locations along with Dr. Antonini in Rome, Italy.
Two shareholders are among the treated patients and can confirm the ease of the treatment for the patient. Testimonials will be published soon.
CELZ added physicians in Hawaii (Sanderson), California, Ohio, Texas and Tennessee (to be named soon) and CELZ will continually add the new physicians to the CaverStem® website as they come aboard. CELZ is adding approximately 5 doctors per month in the most recent two months.
To speed up new physician training due to the demand, CELZ added additional medical personnel to travel to each physicians office to train.
Due to the increased international demand and to compliment the existing relationship with Scott Shea, Thomas Bianchi has joined the company as the international sales representative. DD will tell you that interest in increasing in Europe.
Marketing Director David Brandt has been interviewing patients and is preparing customer testimonial videos. These will be posted soon.
CELZ has started treating the first patients with the FemCelz procedure for the treatment of female sexual dysfunction using stem cells from the patient's own bone marrow. Many of the existing CaverStem® affiliated physician's will also treat female patients for sexual function and we anticipate that they will be the leaders in progressing the FemCelz program. Doctors have been treating the first patients with FemCelz and additional doctors are scheduled to be trained in FemCelz procedures.
Over 50 domain names have been registered showing that MANY more doctors are being vetted or have shown interest. These includes MANY cities and states in the USA, and now we KNOW there are domains registered in Russia (PromoMed, Dr. Pushkar), Germany, France, Switzerland (Alto Uro, Dr. Bachmann) and Austria.
CELZ has begun a series of mailer and email campaigns introducing the CaverStem® procedure to licensed physicians in the areas of urology, OB/GYN, sexual function and plastic surgery. This campaign which will be expanded on a monthly basis with follow up mailers and emails and calls from our sales representatives. It's the goal to reach out to a minimum of 2500 new physicians each month by these methods. CELZ reported good replies from the January emails. Your DD will show you that more interest is building each month.
CELZ has also increased its online presence on Social Media and by placing banner advertising on websites and search engines attracting the active male. They are currently scripting television commercials which will be edited to direct patients to each physician in their area.
U.S. and international agreements have been reached for exclusive distribution rights for the FDA approved Generation 2 bone marrow harvest technology which has been used with multiple ED patients with excellent results, however Government exemptions are required for the ongoing import of the device in Russia. This is a slow and tedious process in getting approval, therefore CELZ progress has been delayed in Russia.
Your DD will show that Dr. Gershman has been performing the procedure with EXCELLENT results…Up to 90% success rate, even in difficult patients. CELZ has received positive feedback from treating physicians of a 70% to 90% efficacy in their patients. Obviously results differ depending on the age and health of the patient and cause and severity of their erectile dysfunction.
A one-year trial has concluded and will PROVE the same results and you can watch it here; https://clinicaltrials.gov/ct2/show/NCT03699943?recrs=deghi&fund=2&lupd_s=09%2F27%2F2018&lupd_d=14
CELZ is working on their paper for publication. This is ongoing and in compliance with contractual obligations. Once the paper has been approved by The Journal of Translational Medicine and a publication date advised, shareholders will be updated. Additionally, CELZ has designed an electronic patient registry that is intended to include data from the clinical trial, data from treating physicians using centrifuge technology with a 30cc to 60cc bone marrow aspiration and the second generation, needle only.
Revenue has now started, CELZ is cash flowing. Additional physicians are scheduled for training, patients are being treated and revenues are being generated and increasing each month. Evidence of this are the scores of patients treated in Rome and NM. CELZ anticipates reaching financial self-sufficiency by revenues from sales in 2019.
CELZ has Institutional Investors now, slowing dilution and providing much better terms as CELZ completes the commercialization phase. The most recent notes that were issued in 2018 were renegotiated providing cash for operations.
CELZ signed with PatientGain to redesigning the website for the anticipated HUGE volume of traffic CaverStem® and FemCelz will generate. This has generated many calls to the vetted doctors.
CELZ anticipates acquiring the Virility Centers of America brand from affiliate company Creative Medical Health, Inc. The use of the Virility Centers brand is related to male and female wellness clinics, including sexual function (CaverStem® and FemCelzTM), incontinence and infertility. This brand will compliment the CaverStem® and FemCelz brands.
CaverStem® and FemCelz are just TWO of SEVERAL patents held by CMTH.
4 NEW patents were applied for in 2018.
CELZ anticipates commercialization of StemSpine in late 2019 or early 2020 bringing online a third revenue source.
Gershman and Ichim have already successfully commercialized Medistem.
CaverStem®, FemCelz, StemSpine & AmnioStem have all be TRADEMARKED
CaverStem is now a REGISTERED TRADEMARK. Caverstem®
We KNOW Caverstem® + FemCelz + StemSpine + AmnioStem = NASDAQ
PLEASE read the sticky posts seen when logging in to iHub through a browser!!
For the new eyes..............
Fully agree ten. +1.
We know buddy.
The day traders who loaded up in the high .006’s, low .007’s who don’t hold over the weekend. Your toxic note is dead. Institutional notes are not being converted under .01. Lots more rumors going on behind the scenes.
$CELZ
They are building a monster for the shareholders who can see the forest for the trees. Scientists and doctors, exactly the opposite of the pumpers we are used too. A rare gem in the OTC.
No argument there from me. I was one of them who invested the lions share then too. I still contend that the issues fell on switching from the centrifugal separator to the needle kit that put everything on hold for months. I will never know if I am right or wrong, but I was confident back then that we would see offices open in late fall, and none of that happened until 2019. That is the most logical reason to me. That is a killer in the OTC and then most are once bitten, twice shy. Even offices opening in 2019 didn’t move the needle.
I strongly believe that is all behind us now and we are back on track. The damage done was the OS and the notes, but much of that is behind us too.
If Antonini and NM keep rocking it, and the other offices ramp up, and the OH, TN, TX, HI and Europe offices open, it’s not hard to imagine the remaining notes being paid back with interest and the company becoming self sufficient.
We shall see, and I can still buy train tickets for under .01. :)
Yup, and a ton has changed since then. Like it or not the toxic note that took us sub penny is dead. This is the third trading day without it and we are trading normal, especially when you can not deny the Q will show the best revs to date. If you are still worried about the company, go watch the doctors videos again. Lots to be happy about. Cash flowing. Self sufficient as soon as 2019.